HPN328-4001 trial: what clinicians have said so far
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
- NCT04471727 ↗
- Active, not recruiting
- Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Focused size, estimated: 1–150 verified statements once built
Discussed at: 2026 ASCO Genitourinary Cancers Symposium
We haven't built an HCP commentary report on HPN328-4001 (gocatamig (MK-6070); gocatamig (MK-6070) plus atezolizumab; gocatamig (MK-6070) plus ifinatamab deruxtecan in advanced DLL3-expressing small-cell lung cancer and neuroendocrine carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Some of the questions raised in the 9 indexed sources
Automated from all 9 indexed sources (Dec 2021 – Jun 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether adding ifinatamab deruxtecan or atezolizumab to MK-6070 offers more than MK-6070 alone in SCLC
- Whether MK-6070 has activity in neuroendocrine prostate cancer and other extrapulmonary neuroendocrine carcinomas
- Whether DLL3 expression should be required to select patients for MK-6070
Indexed commentary on HPN328-4001 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 9 posts on X, typically up to 40 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 With Atezolizumab or Ifinatamab Deruxtecan (I-DXd) in Patients With Advanced Cancers Associated With Expression of Delta-like Canonical Notch Ligand 3 (DLL3).
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Small-Cell Lung Cancer; Neuroendocrine Carcinoma
- Interventions
- Gocatamig; Atezolizumab; Ifinatamab Deruxtecan (I-DXd)
- Arms
- Gocatamig monotherapy dose escalation with 1 week dosing interval · Experimental
- Gocatamig monotherapy dose escalation with 2 week dosing interval · Experimental
- Gocatamig monotherapy dose escalation with 3 week dosing interval · Experimental
- Gocatamig dose escalation with atezolizumab · Experimental
- Gocatamig dose escalation in combination with I-DXd · Experimental
- Enrollment
- 232 (estimated)
- Primary outcomes
- Percentage of participants who experience an adverse event
- Percentage of participants who discontinue due to an adverse event
- Number of participants with dose limiting toxicity (DLT) following treatment with HPN328 as monotherapy or in combination with atezolizumab or I-DXd
- Maximum concentration (Cmax) of Gocatamig
- Cmax of Atezolizumab
- Cmax of I-DXd
- Time to maximum concentration (Tmax) of Gocatamig
- Tmax of atezolizumab
- Tmax of I-DXd
- Area under the concentration-time curve over the dosing interval t (AUCt) of Gocatamig
- AUCt of atezolizumab
- AUCt of I-DXd
- Area under the concentration-time curve extrapolated to infinity (AUCinf) of Gocatamig
- AUCinf of atezolizumab
- AUCinf of I-DXd
- Terminal half-life (t1/2) of Gocatamig
- t1/2 of atezolizumab
- t1/2 of I-DXd
- Single dose clearance (CL) of Gocatamig
- CL of atezolizumab
- CL of I-DXd
- Steady state maximum concentration (Cmax,ss) of Gocatamig
- Cmax,ss of atezolizumab
- Cmax,ss of I-DXd
- Steady state Ctrough (Ctrough,ss) of Gocatamig
- Ctrough,ss of atezolizumab
- Ctrough,ss of I-DXd
- Steady state time to maximum concentration (Tmax,ss) of Gocatamig
- Tmax,ss of atezolizumab
- Tmax,ss of I-DXd
- Area under the steady state concentration-time curve over dosing interval t (AUCt,ss) of Gocatamig
- AUCt,ss of atezolizumab
- AUCt,ss of I-DXd
- Steady state t1/2 (t1/2,ss) of Gocatamig
- t1/2,ss of Gocatamig with atezolizumab
- t1/2,ss of IDXd
- Steady state CL (CL,ss) of Gocatamig
- CL,ss of Gocatamig with atezolizumab
- CL,ss of I-DXd
- Steady state volume of distribution (V,ss) of Gocatamig
- V,ss of atezolizumab
- V,ss of I-DXd
- Steady state accumulation ratio (AC) of Gocatamig
- AC of atezolizumab
- AC of I-DXd
- Sponsor
- Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) with Daiichi Sankyo
- Start
- Dec 14, 2020
- Primary completion
- Jan 28, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT04471727 · updated Feb 24, 2026